focus -WSS

focus

author：fashion 2025-08-12 06:42:09 - browse：8148

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： How CO2 helps viruses stay alive longer in the air

leisure time

WSS

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Bernie Sanders gets little from pharma CEOs on drug prices

Too many hospitalized Covid

Congress must protect the remaining independent doctors

UnitedHealth CEO's Medicaid comments send insurer stocks diving

hotspot

focus

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Latigo launches with $135 million for Vertex

Drug repurposing or repositioning? The language matters

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

ChatGPT in medicine: STAT answers readers' burning questions

Elevance PBM president out as customers face prescription chaos

George Santos makes 1st court appearance after pleading not guilty to 13 counts

For pregnant people, addiction treatment shouldn't mean a call to child protective services

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Tome Biosciences co

knowledge

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Too many hospitalized Covid

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Elevance PBM president out as customers face prescription chaos

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

entertainment

Wikipedia

leisure time

explore